Investigational drug · Phase 2
DYP688
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Uveal Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "DYP688"
First trial start
2022
Jul 4, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DYP688", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Uveal Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "DYP688" as an intervention, largest first.
- A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05415072 · 66 participants · Start Jul 4, 2022 · Primary completion Oct 1, 2027
Drug: DYP688 · For: Metastatic Uveal Melanoma
Sites: Boston, Massachusetts; New York, New York; Westmead, Australia · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.
Carlino MS, Kapiteijn E, Piperno-Neumann S, et al. · Nat Med 2026
- Uveal Melanoma: Changing Paradigms of Treatment.
Piperno-Neumann S · Ocul Oncol Pathol 2026
- QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.
Khera E, Dharmarajan L, Hainzl D, et al. · J Pharmacokinet Pharmacodyn 2024
Also in development for Metastatic Uveal Melanoma
- DarovasertibIDE 196, LXS196Phase 35 trials
IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma
- RP2Phase 32 trials
Replimune, Inc. · Hepatocellular Carcinoma, Biliary Tract Cancer, Metastatic Uveal Melanoma
- VMD-102Single agentPhase 21 trial
VM Discovery, Inc. · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.